Please login to the form below

Not currently logged in
Email:
Password:

Increlex

This page shows the latest Increlex news and features for those working in and with pharma, biotech and healthcare.

EMA publishes European drug shortage details

EMA publishes European drug shortage details

First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... The two other drugs with shortages assessed by the EMA are Ipsen's Increlex (mecasermin), for people with a growth disorder due to severe primary insulin-like growth

Latest news

  • North-South divide?

    As such, treatments for high need, orphan conditions have been approved with costs per QALY potentially above £40, 000 (46, 000), like mecasermin (Increlex) for growth failure in children and nelarabine

  • Reaching new heights

    A compelling video illustrated the case of the first UK patient diagnosed with Severe Primary IGFD and treated with Recombinant human insulin-like growth factor-I (rhIGF-I), Increlex. ... 75 per cent were 'considerably more confident' in using rhIGF-1

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics